Chapter 2. What Is IBS?
Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97:11(suppl):S7–S26.
Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther 1999;13(suppl 12):3–14.
Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108–2131.
Longstreth GF, Burchette RJ. Family practitioners’ attitudes and knowledge about irritable bowel syndrome. Fam Prac 2003;20:670–674.
Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004;126:1665–1673.
O’Sullivan MA, Mahmud N, Kelleher DP, Lovett E, O’Morain CA. Patient knowledge and educational needs in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2000;12:39–43.
Schuster MM. Defining and diagnosing irritable bowel syndrome. Am J Manag Care 2001;7:S246–S251.
Chapter 3. Why Do I Have IBS?
Ali A, Richardson D, Toner B. Feminine gender role and illness behaviour in irritable bowel syndrome. J Gender Culture Health 1998;3:59–65.
Almy TP, Mullin M. Alterations in man under stress. Experimental production of changes stimulating the “irritable colon.” Gastroenterology 1947;8:616– 626.
Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425–432.
Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology 2002;123:1686–1701.
Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657–1664.
Crane C, Martin M. Illness-related parenting in mothers with functional gastrointestinal symptoms. Am J Gastroenterol 2004;99:694–702.
Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Int Med 1990;113:828–833.
Drossman DA, Talley NJ, Leserman J, et al. Sexual and physical abuse and gastrointestinal illness. Ann Int Med 1995;123:782–794.
Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and the persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347:150–153.
Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44:400–406.
Heitkemper MM, Cain KC, Jarrett ME, et al. Symptoms across the menstrual cycle in women with irritable bowel syndrome. Am J Gastroenterol 2003;98:420–430.
Houghton LA, Jackson NA, Whorwhell PJ, et al. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000;95:2296–2300.
Kanazawa M, Endo Y, Whitehead WE, et al. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci 2004;49:1046–1053.
Lackner JM, Gudleski GD, Blanchard EB. Beyond abuse: the association among parenting style, abdominal pain, and somatization in IBS patients. Behav Res Ther 2004;42:41–56.
Lembo T, Zaman MS, Chavez NF, et al. Concordance of IBS among monozygotic and dizygotic twins. Gastroenterology 2001;120:A636.
Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799–804.
Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000;95:451– 456.
Locke GR, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907–912.
Miller V, Whitaker K, Morris JA, Whorwell PJ. Gender and irritable bowel syndrome: the male connection. J Clin Gastroenterol 2004;38:558–560.
Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311–1317.
Neal R, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six-year follow-up study. Gut 2002;51:410–413.
Pata C, Erdal E, Yazici K, et al. Association of the 1438 G/A and 102 T/C polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome. J Clin Gastroenterol 2004;38:561–566.
Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis. BMJ 1999;318:565–566.
Ruigomez A, Rodriguez LA, Johansson S, Wallander MA. Is hormone replacement therapy associated with an increased risk of irritable bowel syndrome? Maturitas 2003;44:133–140.
Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804–811.
Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972–1979.
Whitehead WE, Bosmajian L, Zonderman AB, et al. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988;95:709–714.
Chapter 4. How Common Is IBS?
Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569–1580.
Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282–1284.
National Ambulatory Medical Care Survey. National Center for Health Statistics: NAMCS description. Available at www.cdc.gov/nchs/about/major/ahcd/namcsdes.htm.
Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000;95:2816–2824.
Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1992;101:927–934.
Chapter 5. What Is My Prognosis?
American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, Md. 2001.
Bertram S, Kurland M, Lydick E, et al. The patient’s perspective of irritable bowel syndrome. J Fam Prac 2001;50:521–525.
Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97:11(suppl):S7–S26.
Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001;134:860–868.
Frank L, Kleinman L, Rentz A, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 2002;24:675–689.
Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654–660.
Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a five-year prospective study. Lancet 1987;1:963–965.
Lacy BE, Rosemore, J, Robertson, D, et al. Physicians’ attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol 2006;41:892–902.
Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the patient-physician interaction. Ann Intern Med 1995; 122:107–112.
Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500–1511.
Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736–1741.
Chapter 6. The Anatomy of Digestion
Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499–1506.
Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987;92:1885–1893. Kellow JE, Phillips SF, Miller LJ, et al. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988;29:1236–1243.
Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and non-painful rectal distention. Gastroenterology 2000;118:842–848.
Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14:125–132.
Silverman DHS, Munakata JA, Ennes H, et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997;112:64–72.
Thompson WG, Creed F, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992;5:75–91.
Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl II):43–47.
Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98:1187–1192.
Chapter 7. How Is IBS Diagnosed?
Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002;97:2812–2819.
Chey WD, Olden K, Carter E, et al. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in US women. Amer J Gastroenterol 2002; 97:2803–2811.
Drossman DA. Irritable bowel syndrome: how far do you go in the workup? Gastroenterology 2001;121:1515.
Drossman DA, Corazziari E, Talley NJ, et al. Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. 2nd ed. McLean, Va.: Degnon Associates, 2000.
Kruis W, Thieme CH, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome: its value in the exclusion of organic disease. Gastroenterology 1984;87:1–7.
Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Brit Med J 1978;2:653–654.
Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult celiac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;358:1504–1508.
Smith RC, Greenbaum DS, Vancouver JB, et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991;100:591–595.
Thompson WG, Creed FH, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992;5:75–91.
Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912–2917.
Chapter 9. IBS and Other Medical Disorders
Cady R and Dodick DW. Diagnosis and treatment of migraine. Mayo Clinic Proceedings 2002;77:255–261.
Goadsby PJ, Lipton RB, and Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002;346:257–270.
Chapter 13. Treatment Basics
Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48:272–282.
Camilleri M. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999;13(suppl 12):48–53.
Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136–147.
Klein KB. Controlled treatment trials in the irritable bowel syndrome. Gastroenterology 1988;95:232–241.
Chapter 16. Treatment Options for IBS with Constipation
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344– 2354.
Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329–341.
Ford A, Brandt L, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:183–93.
Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170–177.
Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877–1886.
Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002;47:2222–2230.
Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671–676.
Lacy BE, Cole MS. Constipation in the older adult. Clin Geriatrics 2004;12:44–54.
Lacy BE, Loew B, Crowell MD. Prucalopride for chronic constipation. Drugs Today 2009;45:843–853.
Lacy BE, Yu S. Tegaserod: a new 5-HT4 agonist. J Clin Gastroenterol 2002;34:27–33.
Muller-Lissner S, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, constipation. Aliment Pharmacol Ther 2001;15:1655–1666.
Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–1888.
Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scan J Gastroenterol 2004;39:119– 126.
Patel S, Berrada D, Lembo A. Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opinion Pharmacother 2004;5:2369–2379.
Chapter 17. Treatment Options for IBS with Diarrhea
Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Int Med 2001;161:1733– 1740.
Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984;29:239– 247.
Coremans G, Clouse RE, Carter F, et al. Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance. Gastroenterology 2004;126:A643.
Higgins PDR, Davis KJ, Laine L. The epidemiology of ischemic colitis. Aliment Pharmacol Ther 2004;19:729–738.
Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662–2670.
Chapter 18. Medications for Abdominal Pain Associated with IBS
Broekaert D, Vos R, Gevers A, et al. A double-blind, randomized placebo-controlled crossover trial of citalopram, a selective 5-hydroxytryptamine reup-take inhibitor, in irritable bowel syndrome. Gastroenterology 2001;120:A641.
Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19–31.
Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852–858.
Masand PS, Gupta S, Schwartz TL, et al. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. J Clin Psychiat 2002;4:12–16.
Mathias JR, Clench MH, Abell TL, et al. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease. Dig Dis Sci 1998;43:1347–1355.
Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981;3:153–156.
Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial over-growth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503–3506.
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double blind, randomized controlled study. Am J Gastroenterol 2003;98:412–419.
Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499–510.
Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914–920.
Chapter 19. Treatments for Gas and Bloating
Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:68–72.
Chapter 21. Complementary and Alternative Medicine
Bazzocchi G, Gionchetti P, Almerigi PF, et al. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002;34(suppl):48–53.
Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998;280:1585–1589.
Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895–904.
Niedzielin K, Kordecki H, Birkenfeld B. A controlled double-blind randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143–1147.
Nobaek S, Johansson ML, Molin G, et al. Alternation of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231–1238.
Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and meta-analysis. Am J Gastroenterol 1998;93:1131–1135.
Rohrbock RBK, Hammer J, Vogelsang H, et al. Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. Am J Gastroenterol 2004;99:1990–1997.
Sen S, Mullan MM, Parker TJ, et al. Effect of Lactobacillus plantarum 299V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615–2620.
Spanier JF, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Int Med 2003;163:265–274.
Yadav SK, Jain AK, Tripathi SN, Gupta JP. Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res 1989;90:496–503.
Chapter 22. Psychological, Hypnotherapeutic, and Psychiatric Therapies
Fricchione G. Generalized anxiety disorder. N Eng J Med 2004;351:675–682.
Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long-term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003;52:1623–1629.
Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol 1994;62:576–582.
Heymann-Monnikes I, Arnold R, Florin I, et al. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000;95:981–994.
Jackson JL, O’Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65–72.
Otto MW, Smits JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psych 2004;65 (suppl 15):34–41.
Chapter 24. IBS and Children
Crane C, Martin M. Illness-related parenting in mothers with functional gastrointestinal symptoms. Am J Gastroenterol 2004;99:694–702.
El-Matary W, Spray C, Sandhu B. Irritable bowel syndrome: the commonest cause of recurrent abdominal pain in children. Eur J Pediatr 2004;163:584– 588.
Howell S, Talley NJ, Quine S, et al. The irritable bowel syndrome has origins in the childhood socioeconomic environment. Am J Gastorenterol 2004;99:1572–1578.
Kanazawa M, Endo Y, Whitehead WE, et al. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci 2004;49:1046–1053.
Lackner JM, Gudleski GD, Blanchard EB. Beyond abuse: the association among parenting style, abdominal pain, and somatization in IBS patients. Behav Res Ther 2004;42:41–56.
Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000;95:451– 456.
Miele E, Simeone D, Marino A, et al. Functional gastrointestinal disorders in children: an Italian prospective survey. Pediatrics 2004;114:73–78.